Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 50 million shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday. While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added. Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of vaccines in the global as well as domestic markets as it was felt that there is an urgent need to procure the jabs at a time the country is reeling under an unprecedented second wave of COVID-19 and a widening gap between supply and requirement.
URL copied Image Source : FILE PHOTO/PTI
Currently, the country is using two made-in India jabs Covishield and Covaxin to inoculate its billion-plus population.
Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday.
While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added.
Moderna plans India launch next year for single-dose COVID vaccine
In a high level meeting it was discussed that Moderna doesn t have surplus vaccines to share in 2021 and that it plans to launch its single-dose vaccine for the Indian market only in 2022
PTI | May 25, 2021 | Updated 21:39 IST
US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification
Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday.
Moderna s single-dose COVID-19 vaccine in India likely next year; Pfizer ready with 5 crore doses for 2021
The central government will make its own arrangement for further channelization of procured vaccines in the domestic market.
Share Via Email
| A+A A- By PTI
NEW DELHI: Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday.
While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added.
Moderna s single-dose Covid-19 vaccine in India likely in 2022; Pfizer ready with 5 cr doses for 202
Moderna s single-dose Covid-19 vaccine in India likely in 2022; Pfizer ready with 5 cr doses for 2021
Moderna is in talks with Cipla and other Indian pharma firms to launch its single-dose Covid-19 vaccine in India by next year. Meanwhile, Pfizer has reportedly indicated that it can provide 5 crore doses of its vaccine this year itself.
advertisement
UPDATED: May 25, 2021 22:12 IST
Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of Covid-19 vaccines in the global as well as domestic markets. (Photo: PTI)